Sah Shiv Nandan, Gupta Sumit, Bhardwaj Neha, Gautam Lalit Kumar, Capalash Neena, Sharma Prince
Department of Microbiology, Panjab University, Chandigarh, 160014 India.
Department of Microbiology, Central Campus of Technology, Tribhuvan University, Dharan, Nepal.
In Silico Pharmacol. 2024 Dec 24;13(1):7. doi: 10.1007/s40203-024-00292-3. eCollection 2025.
, an opportunistic and notorious nosocomial pathogen, is responsible for many infections affecting soft tissues, skin, lungs, bloodstream, and urinary tract, accounting for more than 722,000 cases annually. Despite the numerous advancements in therapeutic options, no approved vaccine is currently available for this particular bacterium. Consequently, this study focused on creating a rational vaccine design using bioinformatics tools. Three outer membrane proteins with immunogenic potential and properties of good vaccine candidates were used to select epitopes based on good antigenic properties, non-allergenicity, high binding scores, and a low IC50 value. A multi-epitope peptide (MEP) construct was created by sequentially linking the epitopes using suitable linkers. ClusPro 2.0 and C-ImmSim web servers were used for docking analysis with TLR2/TLR4 and immune response respectively. The Ramachandran plot showed an accurate model of the MEP with 100% residue in the most favored and allowed regions. The construct was highly antigenic, stable, non-allergenic, non-toxic, and soluble, and showed maximum population coverage. Additionally, molecular docking demonstrated strong binding between the designed MEP vaccine and TLR2/TLR4. In silico immunological simulations showed significant increases in T-cell and B-cell populations. Finally, codon optimization and in silico cloning were conducted using the pET-28a (+) plasmid vector to evaluate the efficiency of the expression of vaccine peptide in the host organism (). This designed MEP vaccine would support and accelerate the laboratory work to develop a potent vaccine targeting MDR .
The online version contains supplementary material available at 10.1007/s40203-024-00292-3.
是一种机会性且臭名昭著的医院病原体,可导致许多影响软组织、皮肤、肺部、血液和泌尿道的感染,每年病例超过72.2万例。尽管治疗选择有诸多进展,但目前尚无针对这种特定细菌的获批疫苗。因此,本研究聚焦于使用生物信息学工具进行合理的疫苗设计。利用具有免疫原性潜力且具备良好疫苗候选特性的三种外膜蛋白,基于良好的抗原特性、无致敏性、高结合分数和低IC50值来选择表位。通过使用合适的接头依次连接表位,构建了一种多表位肽(MEP)。分别使用ClusPro 2.0和C-ImmSim网络服务器对TLR2/TLR4进行对接分析以及对免疫反应进行分析。拉氏图显示MEP的精确模型,100%的残基位于最有利和允许的区域。该构建体具有高抗原性、稳定性、无致敏性、无毒性且可溶,并显示出最大群体覆盖率。此外,分子对接表明设计的MEP疫苗与TLR2/TLR4之间有强结合。计算机免疫模拟显示T细胞和B细胞群体显著增加。最后,使用pET-28a(+)质粒载体进行密码子优化和计算机克隆,以评估疫苗肽在宿主生物体()中的表达效率。这种设计的MEP疫苗将支持并加速开发针对耐多药的有效疫苗的实验室工作。
在线版本包含可在10.1007/s40203-024-00292-3获取的补充材料。